Wouter Koek1, Susan L Mercer, Andrew Coop. 1. Department of Psychiatry, The University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78229-3900, USA. koek@uthscsa.edu
Abstract
RATIONALE: Gamma-hydroxybutyrate (GHB) is used to treat narcolepsy but is also abused. GHB has many actions in common with the GABA(B) receptor agonist baclofen. OBJECTIVE: To further study the role of GABA(B) receptors in the effects of GHB. MATERIALS AND METHODS: The experiments examined the ability of the GABA(B) receptor antagonist CGP35348 to attenuate GHB-induced catalepsy in comparison with its ability to attenuate the cataleptic effects of GABA(B) receptor agonists. RESULTS: In C57BL/6J mice, GHB, the GHB precursor gamma-butyrolactone (GBL), and the GABA(B) receptor agonists baclofen and SKF97541 all produced catalepsy but differed in potency (i.e., SKF97541>baclofen>GBL>GHB) and in onset of action. The cataleptic effects of drug combinations were assessed at the time of peak effect of each compound, i.e., 60 min after CGP35348 and 60, 30, 30, and 15 min after baclofen, SKF97541, GHB, and GBL, respectively. At 100 mg/kg, CGP35348 shifted the dose-response curves of baclofen and SKF97541 to the right but not those of GHB and GBL; at 320 mg/kg, CGP35348 shifted the curves of all four compounds to the right. CONCLUSIONS: The finding that CGP35348 was about threefold less potent to antagonize GHB and GBL than baclofen and SKF97541 is further evidence that the mechanisms mediating the effects of GHB and GABA(B) agonists are not identical. Differential involvement of GABA(B) receptor subtypes, or differential interactions with GABA(B) receptors, may possibly explain why GHB is effective for treating narcolepsy and is abused whereas baclofen is not.
RATIONALE: Gamma-hydroxybutyrate (GHB) is used to treat narcolepsy but is also abused. GHB has many actions in common with the GABA(B) receptor agonist baclofen. OBJECTIVE: To further study the role of GABA(B) receptors in the effects of GHB. MATERIALS AND METHODS: The experiments examined the ability of the GABA(B) receptor antagonist CGP35348 to attenuate GHB-induced catalepsy in comparison with its ability to attenuate the cataleptic effects of GABA(B) receptor agonists. RESULTS: In C57BL/6J mice, GHB, the GHB precursor gamma-butyrolactone (GBL), and the GABA(B) receptor agonists baclofen and SKF97541 all produced catalepsy but differed in potency (i.e., SKF97541>baclofen>GBL>GHB) and in onset of action. The cataleptic effects of drug combinations were assessed at the time of peak effect of each compound, i.e., 60 min after CGP35348 and 60, 30, 30, and 15 min after baclofen, SKF97541, GHB, and GBL, respectively. At 100 mg/kg, CGP35348 shifted the dose-response curves of baclofen and SKF97541 to the right but not those of GHB and GBL; at 320 mg/kg, CGP35348 shifted the curves of all four compounds to the right. CONCLUSIONS: The finding that CGP35348 was about threefold less potent to antagonize GHB and GBL than baclofen and SKF97541 is further evidence that the mechanisms mediating the effects of GHB and GABA(B) agonists are not identical. Differential involvement of GABA(B) receptor subtypes, or differential interactions with GABA(B) receptors, may possibly explain why GHB is effective for treating narcolepsy and is abused whereas baclofen is not.
Authors: M A Carai; G Colombo; G Brunetti; S Melis; S Serra; G Vacca; S Mastinu; A M Pistuddi; C Solinas; G Cignarella; G Minardi; G L Gessa Journal: Eur J Pharmacol Date: 2001-10-12 Impact factor: 4.432
Authors: Klemens Kaupmann; John F Cryan; Petrine Wellendorph; Cedric Mombereau; Gilles Sansig; Klaus Klebs; Markus Schmutz; Wolfgang Froestl; Herman van der Putten; Johannes Mosbacher; Hans Bräuner-Osborne; Peter Waldmeier; Bernhard Bettler Journal: Eur J Neurosci Date: 2003-11 Impact factor: 3.386
Authors: W Froestl; S J Mickel; G von Sprecher; P J Diel; R G Hall; L Maier; D Strub; V Melillo; P A Baumann; R Bernasconi Journal: J Med Chem Date: 1995-08-18 Impact factor: 7.446
Authors: Sarah Wurts Black; Stephen R Morairty; Tsui-Ming Chen; Andrew K Leung; Jonathan P Wisor; Akihiro Yamanaka; Thomas S Kilduff Journal: J Neurosci Date: 2014-05-07 Impact factor: 6.167